CIBC Asset Management Inc trimmed its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 23.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,447 shares of the biotechnology company’s stock after selling 10,666 shares during the period. CIBC Asset Management Inc’s holdings in Biogen were worth $6,062,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Caprock Group LLC purchased a new position in Biogen during the 3rd quarter worth $742,000. Leuthold Group LLC acquired a new stake in shares of Biogen in the third quarter valued at about $3,294,000. Generali Investments Management Co LLC lifted its stake in shares of Biogen by 408.2% in the third quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company’s stock valued at $1,397,000 after purchasing an additional 8,008 shares during the period. SG Americas Securities LLC lifted its stake in shares of Biogen by 1,793.8% in the fourth quarter. SG Americas Securities LLC now owns 183,829 shares of the biotechnology company’s stock valued at $32,352,000 after purchasing an additional 174,122 shares during the period. Finally, TD Asset Management Inc increased its holdings in Biogen by 12.7% during the 3rd quarter. TD Asset Management Inc now owns 161,195 shares of the biotechnology company’s stock valued at $22,580,000 after acquiring an additional 18,168 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.
Biogen News Roundup
Here are the key news stories impacting Biogen this week:
- Positive Sentiment: Biogen’s salanersen won FDA Breakthrough Therapy Designation for SMA, with early phase 1b data suggesting meaningful motor improvements and a once-yearly dosing profile that could make the therapy stand out commercially. BIIB’s Next-Gen SMA Therapy Salanersen Wins FDA’s Breakthrough Tag
- Positive Sentiment: Biogen also highlighted progress on BIIB115 in post-gene therapy SMA, adding to investor optimism that the company has multiple shots on goal in a key neurodegeneration market. Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth
- Positive Sentiment: Biogen and UCB presented additional data on dapirolizumab pegol in lupus, showing reduced flare rates and lower steroid use, which supports the drug’s potential in a large autoimmune market. UCB and Biogen build steroid-sparing case for lupus drug
- Neutral Sentiment: Biogen is also facing legal overhang after law firms announced investor investigations and fraud-related claims, which could keep sentiment cautious even as pipeline news improves. BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
- Neutral Sentiment: A separate investor alert from Pomerantz also flagged a claims investigation into Biogen, adding another potential risk factor, though it does not yet indicate any formal enforcement action. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB
Wall Street Analysts Forecast Growth
Read Our Latest Report on BIIB
Biogen Stock Down 0.6%
Shares of NASDAQ:BIIB opened at $195.34 on Friday. The stock has a market capitalization of $28.84 billion, a price-to-earnings ratio of 20.96, a price-to-earnings-growth ratio of 1.72 and a beta of 0.20. Biogen Inc. has a 1-year low of $121.05 and a 1-year high of $205.97. The company’s fifty day moving average is $187.60 and its two-hundred day moving average is $183.33. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06.
Biogen (NASDAQ:BIIB – Get Free Report) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm’s revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities analysts anticipate that Biogen Inc. will post 14.18 EPS for the current year.
Biogen Company Profile
Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.
The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.
Featured Articles
- Five stocks we like better than Biogen
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
